Similar Papers

Paper Title
Journal
Date
Author
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J Schuster ... Lihua E Budde
Blood | VOL. 134
Stephen J Schuster, et. al.Stephen J Schuster ... Lihua E Budde
13 Nov 2019
A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era
Aaron Rosenberg ... Ted Wun
Blood | VOL. 124
Aaron Rosenberg, et. al.Aaron Rosenberg ... Ted Wun
06 Dec 2014
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Greg L Plosker ... David P Figgitt
Drugs | VOL. 63
Greg L Plosker, et. al.Greg L Plosker ... David P Figgitt
01 Jan 2003
Multicenter Analysis of Very Elderly Indolent and Aggressive Non-Hodgkin Lymphoma (NHL): Impact of Functional Status on Outcome,
Chadi Nabhan ... Andrew M Evens
Blood | VOL. 118
Chadi Nabhan, et. al.Chadi Nabhan ... Andrew M Evens
18 Nov 2011
View more papers

More From: Blood

Paper Title
Journal
Date
Author
Brentuximab vedotin and nivolumab for cHL.
-
Blood | VOL. 145
--
16 Jan 2025
B-1 B cells lose self-control in SCD.
David R Gibb ... Sean R Stowell
Blood | VOL. 145
David R Gibb, et. al.David R Gibb ... Sean R Stowell
16 Jan 2025
Is it time to screen for multiple myeloma?
Irene M Ghobrial ... Floris Chabrun
Blood | VOL. 145
Irene M Ghobrial, et. al.Irene M Ghobrial ... Floris Chabrun
16 Jan 2025
Daratumumab for maintenance in myeloma.
Cyrille Touzeau ... Aurore Perrot
Blood | VOL. 145
Cyrille Touzeau, et. al.Cyrille Touzeau ... Aurore Perrot
16 Jan 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.